If you've been exploring medical weight loss options, you've likely encountered two names that have changed the landscape of obesity treatment: semaglutide and tirzepatide. Both are injectable medications that have produced remarkable weight loss results in clinical trials, but they work differently, cost differently, and may suit different people depending on their health profile and goals.
At Zera Health, we prescribe both medications through our licensed telehealth providers, and we get questions about the differences constantly. This guide gives you the clear, honest comparison you need to have an informed conversation with your provider.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally produced in your gut after eating. It signals to your brain that you're full, slows the rate at which food leaves your stomach (gastric emptying), and stimulates insulin release in a glucose-dependent manner, meaning it only triggers insulin when blood sugar rises, reducing hypoglycemia risk.
By mimicking GLP-1, semaglutide keeps these hunger-reducing, blood-sugar-stabilizing signals active far longer than your natural hormone does. The result: you feel full faster, stay satisfied longer, and experience significantly reduced food cravings, especially for high-calorie, ultra-processed foods.
Tirzepatide takes the GLP-1 mechanism and adds a second hormone: glucose-dependent insulinotropic polypeptide (GIP). GIP is another incretin hormone involved in fat storage, energy metabolism, and insulin sensitivity. By activating both GLP-1 and GIP receptors simultaneously, tirzepatide produces a synergistic effect that appears to be more powerful than either hormone alone.
Think of it this way: semaglutide is playing one instrument really well. Tirzepatide is playing two instruments in harmony, and the result is a noticeably louder weight loss effect, as clinical trials have confirmed.
The landmark STEP 1 trial published in the New England Journal of Medicine followed 1,961 adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg weekly alongside lifestyle interventions lost an average of 14.9% of their body weight, compared to 2.4% for placebo. More than one-third of participants lost 20% or more of their body weight.
These results were unprecedented for a non-surgical weight loss intervention at the time of publication. Additional STEP trials confirmed these results across diverse populations, including people with type 2 diabetes (where average weight loss was slightly lower, around 9-10%, due to different metabolic starting points).
The SURMOUNT-1 trial was published in 2022 and stunned the medical community. Over 72 weeks, participants taking the highest dose of tirzepatide (15mg) lost an average of 22.5% of their body weight. Nearly half of participants on the highest dose lost 25% or more, approaching results typically seen only with bariatric surgery.
The SURMOUNT-2 trial in people with type 2 diabetes showed average weight loss of around 15.7% at the highest dose, still outperforming semaglutide's results in similar populations.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Average Weight Loss | ~15% body weight | ~22% body weight |
| Dosing Frequency | Once weekly injection | Once weekly injection |
| Starting Dose at Zera | 0.25mg/week (titrated up) | 2.5mg/week (titrated up) |
| First Month Cost at Zera | From $149 | From $199 |
| Common Side Effects | Nausea, fatigue, constipation | Nausea, diarrhea, reduced appetite |
| Best For | First-time GLP-1 users, cost-conscious, mild-moderate weight goals | Higher weight loss goals, prior GLP-1 users, metabolic syndrome |
| FDA Approval (weight) | Wegovy® approved 2021 | Zepbound® approved 2023 |
Both medications share a similar GLP-1-driven side effect profile, primarily affecting the gastrointestinal system. The most common side effects include:
In clinical trials, tirzepatide showed slightly higher rates of gastrointestinal side effects at higher doses, particularly nausea and diarrhea, compared to semaglutide. However, the tolerability profile was still considered acceptable by the vast majority of participants, and most side effects resolved after the titration phase.
Semaglutide may have a slight edge in tolerability for people who are particularly sensitive to nausea. Tirzepatide, however, appears to cause less constipation in some users, possibly due to the GIP component influencing gut motility differently.
Both medications carry the same FDA label warnings: a potential risk of thyroid C-cell tumors (observed in rodent studies, human significance is unknown), pancreatitis, gallbladder disease, and kidney problems secondary to dehydration. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) should not use either medication. Your Zera Health provider will screen for these contraindications during your intake assessment.
Branded GLP-1 medications like Wegovy® and Zepbound® can cost over $1,000/month without insurance. At Zera Health, we work with licensed compounding pharmacies to provide compounded semaglutide and tirzepatide at a fraction of the cost:
Both medications are shipped directly to your door, with a comprehensive program that includes provider consultations, dosing guidance, and ongoing support from our clinical team.
Yes. Many patients start with semaglutide and transition to tirzepatide if they want to accelerate results or if they've plateaued. Your Zera Health provider will guide the transition and adjust dosing appropriately. There's typically a brief washout consideration, but switching is very manageable.
Most patients begin to notice reduced appetite and some weight loss within the first 2–4 weeks. Meaningful weight loss (5%+ of body weight) is typically visible by months 2–3. Maximum results are generally achieved after 9–12 months of consistent use at therapeutic doses.
Not necessarily, but the research shows that weight tends to return after stopping, because obesity is a chronic condition with underlying hormonal drivers. Many patients stay on a maintenance dose long-term. Others use GLP-1s for 12–18 months to achieve their goal weight, then work with their provider to transition off gradually while implementing lifestyle changes to maintain results.
Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredient as the branded versions. They are prepared by licensed 503A/503B compounding pharmacies and are subject to quality testing. The key difference is cost, compounding allows access without the brand-name markup.
Both medications slow gastric emptying, which can affect the absorption of oral medications. If you take medications that require precise timing (such as certain thyroid drugs, blood thinners, or contraceptives), discuss this with your provider. GLP-1s can also enhance the blood sugar-lowering effects of diabetes medications like metformin or insulin, so dose adjustments may be needed.
There's no universal answer, it depends entirely on your individual health history, goals, and preferences. However, providers often recommend starting with semaglutide for first-time GLP-1 users and considering tirzepatide for patients with higher weight loss targets or those who have more complex metabolic conditions. The best recommendation comes after a thorough intake review, which your Zera provider will conduct.
Complete your free online assessment and a licensed Zera Health provider will determine which medication is right for you, no in-person visit required.
Start with Semaglutide → Start with Tirzepatide →Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require a valid prescription from a licensed provider. Results vary by individual. Compounded medications are not FDA-approved drug products. Always consult a healthcare professional before starting any new medication.